for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ContraFect Corp

CFRX.OQ

Latest Trade

0.30USD

Change

0.00(+1.63%)

Volume

74,630

Today's Range

0.29

 - 

0.30

52 Week Range

0.27

 - 

2.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.30
Open
0.29
Volume
74,630
3M AVG Volume
6.27
Today's High
0.30
Today's Low
0.29
52 Week High
2.60
52 Week Low
0.27
Shares Out (MIL)
79.41
Market Cap (MIL)
23.82
Forward P/E
-2.55
Dividend (Yield %)
--

Next Event

Q4 2019 ContraFect Corp Earnings Release

Latest Developments

More

Contrafect Reports Q3 Loss Per Share Of $0.07

Contrafect Q2 Loss Per Share $0.11

Contrafect Reports Q1 Earnings Per Share Of $0.15

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ContraFect Corp

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.

Industry

Biotechnology & Drugs

Contact Info

28 Wells Ave Ste 3

+1.914.2072300

https://www.contrafect.com/

Executive Leadership

Roger J. Pomerantz

Chairman of the Board, Chief Executive Officer

Michael Messinger

Chief Financial Officer

Nancy Dong

Vice President, Controller

Cara M. Cassino

General Counsel, Secretary, Chief Medical Officer

Natalie Bogdanos

General Counsel and Corporate secratary

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.850

2017

-0.280

2018

-0.500

2019(E)

-0.100
Price To Earnings (TTM)
5.46
Price To Sales (TTM)
--
Price To Book (MRQ)
2.59
Price To Cash Flow (TTM)
5.13
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
18.19
Return on Equity (TTM)
15.48

Latest News

Latest News

BRIEF-ContraFect Announces Q1 Loss Per Share $0.26

* CONTRAFECT - AS OF MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $39.9 MILLION, COMPARED TO $46.9 MILLION AS OF DECEMBER 31, 2017

BRIEF-ContraFect announces Q3 loss per share $0.02

* ContraFect Corp - As of Sept 30, 2017, had cash, cash equivalents and marketable securities of $52.6 million compared to $35.2 million as of December 31, 2016 Source text for Eikon: Further company coverage:

BRIEF-Contrafect Corp files for mixed shelf offering of upto $100 mln

* Contrafect Corp files for mixed shelf offering of upto $100 million - sec filing Source text (http://bit.ly/2ptEPvU) Further company coverage:

BRIEF-Contrafect Q4 earnings per share $0.01

* Contrafect reports fourth quarter and full year 2016 financial results and provides business update

BRIEF-ContraFect chairman and CEO Steven Gilman takes temporary medical leave

* ContraFect chairman and CEO Steven C. Gilman takes temporary medical leave

BRIEF-Contrafect provides program update

* Now expects to initiate phase 2 study of CF-301 in patients with staphylococcus aureus bacteremia in mid-2017

BRIEF-Contrafect announces expanded research collaboration with the Rockefeller University

* Contrafect announces expanded research collaboration with the Rockefeller University to identify Lysin Therapeutics targeting gram-negative bacteria Source text for Eikon: Further company coverage:

BRIEF-Contrafect Q3 loss per share $0.28

* Contrafect reports third quarter 2016 financial results and provides business update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up